Nuvilex and SG Austria Introduce Revolutionary Treatment for Diabetes Utilizing Live Cell Encapsulation Technology

Diabetes Treatment Expenditures Estimated to Exceed $378 Billion USD by 2013

SILVER SPRING, Md.--(BUSINESS WIRE)-- Nuvilex, Inc. (OTCQB:NVLX) announced today their affiliate SG Austria and partners have successfully treated diabetes in an established, recognized animal model utilizing live encapsulated cells.

The introduced cells responded to elevated blood sugar levels by producing insulin, alleviating the symptoms of diabetes. Moreover, encapsulated cells remained viable and responsive for many months.

These data, as well as previously published results, show it is feasible to overcome the basis for diabetes by implanting encapsulated, insulin-producing cells and pave the way for future clinical trials of encapsulated cells as a means to continuously regulate blood glucose for months, eliminating the need for daily glucose assessment and insulin injections. Such treatment would represent a more natural means of providing insulin to patients that mimics the body's own production, thereby maintaining healthy blood glucose levels.

Diabetes long term effects include kidney failure, amputations, blindness, heart disease and stroke. The World Health Organization (WHO) reports 346 million people worldwide have diabetes and 4 million deaths occur each year as a result. WHO believes, without intervention, these numbers will double by 2030. November 14th was World Diabetes Day to raise diabetes awareness by The International Diabetes Federation (IDF) and WHO, marking Frederick Banting’s birthday, who in 1922 with Charles Best, were influential in insulin’s discovery.

IDF and WHO report more than $378 Billion USD/per year are spent on diabetes treatment, predicting it to be more than $490 billion by 2030. Nuvilex is hoping through this treatment to provide better patient outcomes and acquire a proportionate share of this market in the coming years.

Dr. Robert Ryan, President and CEO of Nuvilex stated, "We look forward to the day when people will no longer have to rely on daily insulin injections. Our goal is for patients to receive encapsulated live cell treatments at most every 3 to 6 months, dramatically changing their lives. I believe investors will continue to appreciate the cutting edge technology and recognize us as an innovative leader in the biotechnology and clinical treatment arenas. ”

About Nuvilex

Nuvilex, Inc. (OTCQB:NVLX) is becoming an international biotechnology provider of clinically useful therapeutic live encapsulated cells and services for encapsulating live cells for the research and medical communities. In addition, all aspects of our corporate activities alone, and in particular in concert with SG Austria, continue to makes strides toward completion. Our oncology offerings will include cancer treatments using the company’s industry-leading live-cell encapsulation technology. Current natural products also carried by Nuvilex include BiaDiagnostics certified Gluten-Free Cinnergen™, 3 oz. travel size Cinnergen™, Cinnechol™ and others to enhance a healthy lifestyle, cosmetic use, flu treatment, tattoo inks, antimicrobial and antinematodal agents.

Safe Harbor Statement
This information may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Nuvilex’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.



CONTACT:

Marmel Communications, LLC
Marlin Molinaro, 702-434-8692
[email protected]

KEYWORDS:   United States  North America  Maryland  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Oncology  Pharmaceutical  Research  Other Science  Diabetes  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.